Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
about
Development of a new vaccine for the prevention of Lassa fever.Vesicular stomatitis virus with the rabies virus glycoprotein directs retrograde transsynaptic transport among neurons in vivoHybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectorsVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expressionProtection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animalsType III interferon attenuates a vesicular stomatitis virus-based vaccine vector.Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alphaNonsegmented negative-strand viruses as vaccine vectors.Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infectionsVaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.Successful topical respiratory tract immunization of primates against Ebola virus.The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceFormulation and delivery of vaccines: Ongoing challenges for animal management.Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.Use of viral vectors for the development of vaccines.Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeuticsEbola virus disease candidate vaccines under evaluation in clinical trials.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumorsOvercoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitorsVesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication.Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cellsLive virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activityReplication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA.Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideOncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Immunogenicity in African Green Monkeys of M Protein Mutant Vesicular Stomatitis Virus Vectors and Contribution of Vector-Encoded Flagellin.
P2860
Q21563440-41984F0A-468B-4CE0-9183-779244D5B574Q24625780-64082A81-B85A-44A8-9DC5-C73A7D9147BDQ27485876-D3640518-548C-413D-B659-5B75AFAD0C7BQ30361939-493507D2-C6C6-4D77-9289-27A7AB8C0DEEQ30370147-E0E68F50-4D0B-4D1D-B7DF-2651C167EA8EQ30495981-50409538-ADFF-4D8C-89D3-384751793168Q33725635-28A98843-B501-4969-8DEC-4AF02FB2ACC2Q34092753-10133641-CD9B-4DE1-B62D-CB99F9503374Q34172295-7534901D-1DFC-4808-AA79-B73368C34841Q34228558-81339C7C-6238-4C86-9C26-C79500470ED8Q34262131-40401AF5-C383-427A-8EFA-3A80382521B9Q34647625-0F5EC2FD-3249-4927-A4E9-5D4DBDAA1ABDQ34717937-8926B5DA-A9AE-42DA-A29B-8409E285E274Q35139219-6F64F5F6-05FA-4258-AA6A-D6A9B5383640Q35557184-048AE186-A518-4D33-A0F9-75A3BC3E1D06Q35751946-23A317D4-8EA1-4C32-AB62-D2009B61A27FQ35857218-A92F30B6-BBD1-4809-A0CA-86F2CEE3CEECQ35867988-679EEEEE-4877-4335-A61D-E38BA455B633Q36423935-817BD01B-D309-40DC-97F7-82BE6E7F39ECQ36470265-748F8F89-96C6-4BA4-99B7-E3BC7C899E09Q36672543-A13E32D8-BEFC-4082-9659-019FC2D198FBQ36780156-40548940-D3AA-4CBF-BE89-399AB077C7B8Q37243886-2B931FA9-36E2-4B66-91AE-A900D707CE17Q37643980-DE4D2C31-E6BA-400F-8E2B-44085354E474Q38363535-7F40F6F9-47E5-441E-AC61-9C4DEA93B62AQ38830109-15F96003-ED6E-4F77-85E4-E5F711021F9DQ38886667-C8B9D018-5324-4DEB-822B-EC7FAB25EE0DQ39096636-D7A09289-CD31-46BD-AC9B-2DA1E6102377Q39610541-97865B07-2B89-4DAD-A38C-2BE089F4C0A5Q39776032-FE3CB276-B523-4D98-AADE-6DE6A8F9DE51Q40619713-955A63E9-7EBC-4FD7-B9AA-CF50EFA7E7E8Q41625843-96C990C7-DCFE-4F69-B709-199A5C9A716DQ41770092-B64E6568-9926-4C8D-B0F4-AD3301FC56CEQ42036085-8AC3E5A8-314D-4610-9D5C-1C3D257DD094Q42157100-D2A8BBD8-740D-4CC9-AA5A-1AA32AE096CEQ52688581-979C9240-567C-4646-8E9B-473B033A904BQ53699705-FFDE0071-0996-49A2-987A-2D04BB1324D3
P2860
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of nonpathoge ...... ent cellular immune responses.
@en
Characterization of nonpathoge ...... ent cellular immune responses.
@nl
type
label
Characterization of nonpathoge ...... ent cellular immune responses.
@en
Characterization of nonpathoge ...... ent cellular immune responses.
@nl
prefLabel
Characterization of nonpathoge ...... ent cellular immune responses.
@en
Characterization of nonpathoge ...... ent cellular immune responses.
@nl
P2093
P2860
P1433
P1476
Characterization of nonpathoge ...... ent cellular immune responses.
@en
P2093
Elizabeth Ramsburg
Jean Publicover
John K Rose
P2860
P304
P356
10.1128/JVI.78.17.9317-9324.2004
P407
P577
2004-09-01T00:00:00Z